

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 64862

Title: Current challenges in applying gene-driven therapies in clinical lung cancer practice

Reviewer's code: 05046795

Position: Peer Reviewer

Academic degree: PhD

Professional title: Research Assistant Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Finland

Manuscript submission date: 2021-02-25

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-03-31 04:23

Reviewer performed review: 2021-04-09 03:49

Review time: 8 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

This review is mainly focus on the status of lung cancer target therapy. The title should narrow to "lung cancer". The progression and "challenges" of target therapy in lung cancer should be focused. The developing targeting drugs and new therapeutical targets in lung cancer should be addressed.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 64862

Title: Current challenges in applying gene-driven therapies in clinical lung cancer practice

Reviewer's code: 05689788

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Finland

Manuscript submission date: 2021-02-25

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-04-01 08:04

Reviewer performed review: 2021-04-12 14:34

Review time: 11 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The manuscript entitled “Current challenges in applying gene-driven therapies in clinical oncology practice” by Jatta Saarenheimo discussed the problem of gene-targeted therapies in lung cancer and it would be helpful for clinical practice. I think the title may be too general, it would be better to focus on lung cancer. Current challenges in applying gene-driven therapies in lung cancer of clinical practice may be better. Besides, could the authors discuss the different strategies of non-small cell lung cancer(NSCLC) and small cell lung cancer (SCLC) in gene driven therapy? Since gene mutation in NSCLC and SCLC varied.